People

Brian A. Johnson

Partner

Vice Chair, Corporate Practice Group

Co-Chair, Capital Markets

johnson-brian.jpg

Brian Johnson has extensive experience representing public and private companies and financial institutions, including investment banking clients, in a wide variety of corporate finance and other strategic transactions. He also advises clients on a regular basis on general corporate and securities law and governance matters. Mr. Johnson represents clients in a range of industries and has a particular focus on life sciences and emerging growth companies.

Learn more about Mr. Johnson's practice and how he can support your startup on WilmerHaleLaunch.com.

Honors & Awards

  • Recommended in the 2016 and 2017 editions of The Legal 500 United States for finance: capital markets: debt offerings and finance: capital markets: equity offerings: advice to managers

Publications & News

View

June 9, 2017

The Legal 500 United States 2017 Recognizes 125 WilmerHale Lawyers Across 28 Practice Areas

The Legal 500 United States has released its 2017 rankings, recommending 125 WilmerHale lawyers—including 12 who are named to its elite “Leading Lawyers” list and two on its “Next Generation Lawyers” list—and 28 practice areas in its 11th edition.

January 27, 2017

Ocular Therapeutix Announces Public Offering of Common Stock

Ocular Therapeutix, Inc. announced the pricing of its registered underwritten public offering of 3,571,429 shares of its common stock.

October 4, 2016

Sarepta Therapeutics and Summit Enter into Exclusive License and Collaboration Agreement

WilmerHale client Summit Therapeutics plc and Sarepta Therapeutics announced that they have entered into an exclusive license and collaboration agreement granting Sarepta rights in Europe, as well as in Turkey and the Commonwealth of Independent States.

September 22, 2016

WilmerHale Reps Eleven Biotherapeutics in Acquisition of Viventia Bio

The acquisition creates a NASDAQ-listed company focused on the development of novel therapies based upon antibody fragments genetically fused to cytotoxic proteins, or targeted protein therapeutics, as new treatments in areas of oncology with significant unmet need.

August 17, 2016

WilmerHale Reps Eleven Biotherapeutics in License Agreement with Roche for Antagonist Antibody Technology

WilmerHale represented Eleven Biotherapeutics, a biopharmaceutical company researching and developing protein therapeutics to treat diseases of the eye, in the negotiation of a license agreement with Roche for Eleven's IL-6 antagonist monoclonal antibody program, including its preclinical ophthalmic drug EBI-031.

July 18, 2016

WilmerHale Advises Intercept Pharmaceuticals in $460M Public Offering

Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, has announced the closing of an underwritten public offering of $460 million aggregate principal amount of 3.25% convertible senior notes due 2023.

June 22, 2016

The Legal 500 United States 2016 Recognizes 111 WilmerHale Lawyers Across 30 Practice Areas

The guide's rankings are based on a series of criteria, including client feedback, interviews with private practice lawyers, and its own research.

October 8, 2014

Actavis to Acquire Durata Therapeutics, Inc.

On October 6, 2014, WilmerHale client Durata Therapeutics announced that it had entered into a definitive merger agreement with Actavis plc under which a subsidiary of Actavis will commence a tender offer to acquire all of the outstanding shares of Durata common stock.

August 29, 2014

Q&A With WilmerHale’s Brian Johnson

A question and answer interview with Brian Johnson, published in Law360 on August 29, 2014.

May 20, 2014

Ophthotech Corporation Enters into Ex-US Licensing and Commercialization Agreement for Fovista® with Novartis

On May 19, 2014, WilmerHale client Ophthotech Corporation announced that the company had entered into an ex-US licensing and commercialization agreement with Novartis Pharmaceuticals focused on the treatment of wet age-related macular degeneration (AMD).

Recent Highlights

Corporate Finance

Mr. Johnson's recent corporate finance transactions include the following:

  • Initial public offerings representing Nabriva Therapeutics, Summit Therapeutics, Ocular Therapeutix, Eleven Biotherapeutics, Ophthotech, PTC Therapeutics, Durata Therapeutics, Merrimack Pharmaceuticals, Verastem and Emergent BioSolutions 
  • Initial public offerings representing the underwriters for ProQR Therapeutics, Aegerion Pharmaceuticals, NuPathe, Visicu and Targacept
  • Numerous follow-on offerings of equity and debt securities representing Intercept Pharmaceuticals, PTC Therapeutics, Ocular Therapeutix, Ophthotech, Merrimack Pharmaceuticals, Durata Therapeutics, Savient Pharmaceuticals, Idenix Pharmaceuticals, Aspect Medical Systems, Millennium Pharmaceuticals, Inc., Thermo Electron and Critical Therapeutics
  • Venture capital and private financings representing a large number of companies and venture capital firms as investors

M&A

Mr. Johnson represents acquirors and targets in the life sciences, technology and information services industries in a variety of acquisition and strategic transactions.

Professional Activities

Mr. Johnson is a member of the Association of the Bar of the City of New York.

Practices

Skip Navigation Links.

Education

JD, magna cum laude, New York University School of Law, 1999, Order of the Coif

BA, Economics and Political Science, cum laude, Tufts University, 1995

Bar Admissions

New York

Skip Navigation Links.